查找临床试验
已按「血友病」检索，对应国际通用词 hemophilia
共找到 29 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 00:19，每 5 分钟自动同步Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
China
年龄 18 Years – 不限
Shanghai Xinzhi BioMed Co., Ltd.
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
China
年龄 不限 – 不限
Yigeng Cao,MD,PhD
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
United States、Belgium、Brazil、Canada、China 等 12 国
年龄 1 Year – 11 Years
Sanofi
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
China
年龄 18 Years – 65 Years
Institute of Hematology & Blood Diseases Hospital, China
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
United States、Argentina、Austria、Brazil、China 等 12 国
年龄 12 Years – 不限
Hoffmann-La Roche
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
China
年龄 0 Years – 18 Years
Runhui WU
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
United States、Canada、Japan、Taiwan
年龄 12 Years – 不限
Sanofi
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
China
年龄 12 Years – 65 Years
Institute of Hematology & Blood Diseases Hospital, China
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
China
年龄 12 Years – 18 Years
Institute of Hematology & Blood Diseases Hospital, China
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
United States、Argentina、Australia、Brazil、Canada 等 12 国
年龄 1 Year – 74 Years
Pfizer